Overture Life Opens First U.S. Clinical Lab and Operations Hub in Dallas as AI-Powered IVF Robotics Headquarters

Audio By Carbonatix

DALLAS--(BUSINESS WIRE)--Oct 23, 2025--

Overture Life, the company behind the world's first babies born from robotic fertilization and robotic egg freezing, today announced the opening of its Dallas facility at 4621 Ross Avenue in The Bogart Building. The site will run non-invasive, CLIA-licensed embryo-assessment testing that analyzes molecules in the fluid surrounding embryos (metabolomics) with machine-learning support, giving fertility teams objective data to inform embryo selection without a biopsy. It will also serve as Overture's U.S. clinical operations headquarters.

The Dallas facility is Overture's first dedicated U.S. laboratory, positioning the company to accelerate deployment of its automated IVF platforms that currently operate in clinics across Brazil, Argentina, Chile, Bolivia, Panama, Turkey, and New Jersey.

"This Dallas hub bridges our European manufacturing and research operations with North American markets," said Hans Gangeskar, CEO of Overture Life. "The central U.S. location facilitates national logistics while giving us access to the biomedical engineering and data science talent concentrated in Texas."

The Old East Dallas site, near Uptown, will anchor Overture's U.S. expansion as demand builds for its DaVitri automated egg-freezing system. The platform freezes eggs with robotic precision, achieving a 12% improvement in egg survival rates while allowing clinics to process three times the number of procedures without adding staff.

Hafsa Irfan, Head of Clinical Operations for the Dallas facility, will oversee the laboratory's scientific build-out and operations, and metabolomics assay optimization. Irfan said, "The infrastructure we're establishing here, from our non-invasive embryo assessment technology to quality systems, creates the foundation for scaling automated fertility care across the United States."

The laboratory equipment and infrastructure represent a multi-million-dollar investment in advanced technical capabilities. The facility will focus on non-invasive embryo testing that provides fertility teams with molecular data to guide treatment decisions without requiring embryo biopsies. The facility's design accommodates expanded laboratory services and continued advancement of AI-driven automation protocols, including building a continuously learning, regulated automation layer, which is the infrastructure that makes AI-driven IVF reproducible, measurable, and clinically validated.

Dallas emerged as the location choice due to its concentration of life sciences companies, proximity to research institutions including UT Southwestern Medical Center, and growing biomedical workforce. The region's biomedical sector employs over 27,000 professionals across 850 companies, with particular strength in medical device development and clinical research.

Overture's automation portfolio addresses the most technically demanding procedures in IVF. The company's ICSI.A system achieved the world's first babies born from robotic sperm injection in 2024. Its DaVitri platform standardizes the egg freezing process that typically requires years of specialized training. Together, these systems help laboratories deliver consistent results while reducing the physical strain on embryologists who perform thousands of precise manual procedures annually.

Overture will be hiring for positions across product development, clinical operations, laboratory operations, manufacturing, quality assurance, regulatory affairs, and commercial functions at the Dallas facility. The site will also coordinate with Overture's research and development operations in Spain and its growing network of clinical partners.

The Dallas laboratory joins Overture facilities in Spain as the company builds infrastructure to meet growing demand. The DaVitri system's European pre-order waitlist, launched in September, filled within weeks as clinics sought automation systems with documented healthy births and peer-reviewed clinical outcomes.

About Overture Life

Overture Life is a biotechnology company building the next generation of automated reproductive laboratories. Its platform integrates robotics, microfluidics, and AI-based analytics to make IVF and related fertility procedures more precise, consistent, and accessible. The company has achieved the world’s first live births from both robotic fertilization and robotic egg freezing and operates programs across Europe and Latin America, with U.S. operations now headquartered in Dallas, Texas. Backed by leading investors including Khosla Ventures, GV (Google Ventures), and the European Investment Bank, Overture Life is advancing automation as the new standard for global reproductive medicine.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251023166706/en/

CONTACT: Media Contact

Patrick Schmidt

[email protected]

KEYWORD: TEXAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: DATA MANAGEMENT WOMEN PRACTICE MANAGEMENT TECHNOLOGY RESEARCH ROBOTICS FAMILY APPS/APPLICATIONS CONSUMER COMMERCIAL BUILDING & REAL ESTATE CONSTRUCTION & PROPERTY PARENTING MEDICAL DEVICES BABY/MATERNITY HEALTH TECHNOLOGY GENETICS CLINICAL TRIALS ARTIFICIAL INTELLIGENCE BIOTECHNOLOGY HEALTH SCIENCE

SOURCE: Overture Life

Copyright Business Wire 2025.

PUB: 10/23/2025 09:00 AM/DISC: 10/23/2025 09:00 AM

http://www.businesswire.com/news/home/20251023166706/en